{"id":4019,"date":"2026-10-29T07:00:00","date_gmt":"2026-10-29T06:00:00","guid":{"rendered":"https:\/\/modafinil.pl\/?p=4019"},"modified":"2026-10-08T14:12:06","modified_gmt":"2026-10-08T12:12:06","slug":"bromantane-mechanism-of-action-origin-of-actoprotector-concept","status":"publish","type":"post","link":"https:\/\/modafinil.pl\/en\/bromantane-mechanism-of-action-origin-of-actoprotector-concept\/","title":{"rendered":"Bromantane: Mechanism of Action and the Actoprotector Idea"},"content":{"rendered":"

Bromantane entered Western awareness sideways \u2014 through doping control at the 1996 Olympic Games, when a substance that laboratories could not immediately identify was detected in samples from several athletes.<\/strong> It was then described in the literature as a new doping agent.1<\/a><\/sup> Meanwhile, the compound already had well over a decade of research behind it \u2014 except that this research had been published in Russian and was therefore practically absent from English-language circulation.<\/p>\n

This text reconstructs what follows from that literature: which chemical family bromantane comes from, what was measured in the dopaminergic system, where the term “actoprotector” came from, and where the limits of this body of evidence lie. In our catalog, bromantane is a chemical reagent with CAS number 87913-26-6<\/a>, and the entire review below concerns exclusively published research.<\/p>\n

Identity card<\/h2>\n

The values in the table come from the PubChem database (record CID 4660557<\/a>), as of 2026-07-03. We give the date because database entries are sometimes updated, and a number without information about when it was measured goes out of date imperceptibly.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
CAS number<\/th>\n87913-26-6<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC16<\/sub>H20<\/sub>BrN<\/td>\n<\/tr>\n
Molar mass<\/th>\n306.24 g\/mol<\/td>\n<\/tr>\n
Systematic name<\/th>\nN-(4-bromophenyl)adamantan-2-amine<\/td>\n<\/tr>\n
InChIKey<\/th>\nLWJALJDRFBXHKX-UHFFFAOYSA-N<\/code><\/td>\n<\/tr>\n
SMILES<\/th>\nC1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br<\/code><\/td>\n<\/tr>\n
Partition coefficient (logP)<\/th>\n5<\/td>\n<\/tr>\n
Topological polar surface area<\/th>\n12 \u00c5\u00b2<\/td>\n<\/tr>\n
Hydrogen bond donors \/ acceptors<\/th>\n1 \/ 1<\/td>\n<\/tr>\n
GHS pictograms<\/th>\nGHS07<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Family: adamantanes<\/h2>\n

Bromantane belongs to the derivatives of adamantane \u2014 a hydrocarbon whose skeleton resembles a fragment of the diamond lattice. This cage is rigid, strongly hydrophobic, and chemically fairly inert, which gives the entire family characteristic physicochemical properties: good lipid solubility, high thermal stability, and a tendency to sublime.<\/p>\n

Adamantane derivatives were studied extensively in the USSR, including with regard to increasing the body’s resistance to extreme conditions.2<\/a><\/sup> Comparisons of several compounds of this family at once \u2014 adapromine, midantane, and bromantane \u2014 in a single experimental setup were also published.3<\/a><\/sup> For a reader accustomed to Western literature, this is unusual: there, adamantanes are associated mainly with amantadine and antiviral drugs, not with a separate branch of research on resistance to stress loads.<\/p>\n

What was measured in the dopaminergic system<\/h2>\n

The most frequently cited paper in this thread dates from 1995 and concerned the effect of bromantane on the dopaminergic and serotonergic systems of the rat brain.4<\/a><\/sup> In the same year, the compound was also described as a substance with immunostimulant and psychostimulant action in animal models.5<\/a><\/sup> Separately, its pharmacological properties were analyzed as a whole.6<\/a><\/sup><\/p>\n

One must be precise here about the status of these findings. These are preclinical studies in animals<\/strong>, performed using methods available in the 1990s and mostly published in Russian-language journals. They show that the dopaminergic system responds \u2014 but they do not settle by exactly which molecular mechanism the response occurs.<\/p>\n

The literature contains the hypothesis that bromantane does not act like classical catecholamine-releasing substances but instead affects neurotransmitter synthesis over a longer time scale. It is indirectly supported by the time profile observed in the studies: relationships between the pharmacokinetic course and the development of the effect were described,7<\/a><\/sup> and pharmaco-electroencephalographic analyses showed a picture different from the pattern typical of stimulants.8<\/a><\/sup> A comparison with sydnocarb in a model of long-term operant conditioning also yielded a profile unlike the reference pattern.9<\/a><\/sup> These are indications consistent with the hypothesis \u2014 not proof of it.<\/p>\n

The concept of the actoprotector<\/h2>\n

Soviet pharmacology developed a category that has no good counterpart in Western nomenclature: the actoprotector<\/em> \u2014 a compound intended to increase performance under load without classical stimulation. A review of this class of compounds appeared in English only in 2012.10<\/a><\/sup><\/p>\n

Research in this line covered the physical work capacity of laboratory animals,11<\/a><\/sup> protective action under conditions of body overheating,12<\/a><\/sup> and a broader rationale for using agents that increase resistance to extreme factors.13<\/a><\/sup> Papers were also published on the neuro- and psychophysiological effects of administration14<\/a><\/sup> and on the characteristics of neuropsychotropic activity in animal models.15<\/a><\/sup> A separate thread concerned differences between mouse strains with differing emotional reactivity.16<\/a><\/sup><\/p>\n

It is worth noting that the concept of the actoprotector is today sometimes juxtaposed with the broader and much looser category of adaptogens, whose history and perspectives have been discussed separately.17<\/a><\/sup> This juxtaposition is, however, problematic: actoprotectors were defined by specific experimental models, adaptogens \u2014 by much more general criteria.<\/p>\n

Toxicological studies<\/h2>\n

This part of the literature is relatively well documented and, for the recipient of the reagent, the most concrete. Published work includes an acute toxicity study,18<\/a><\/sup> an assessment of the effect of a single administration on the neurological status of animals,19<\/a><\/sup> a two-month observation,20<\/a><\/sup> a comprehensive assessment of the effect on behavior,21<\/a><\/sup> as well as papers on the cardiovascular and sympathoadrenal systems22<\/a><\/sup> and on the peripheral blood picture.23<\/a><\/sup> The effect on the postnatal development of offspring was studied separately.24<\/a><\/sup><\/p>\n

All of these studies concern laboratory animals. Their significance for someone working with the material in the laboratory lies in the fact that they describe the range of endpoints studied \u2014 not in allowing any conclusions to be drawn about humans.<\/p>\n

What this literature does not settle<\/h2>\n

A rigorous review must indicate the limits of the body of evidence, and in this case they are clear.<\/p>\n